Which of the following are signs and symptoms of hyperthyroidism select all that apply?

1. Hedberg CW, Fishbein DB, Janssen RS, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med. 1987;316:993–98. [PubMed] [Google Scholar]

2. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–54. [PubMed] [Google Scholar]

3. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99:923–31. [PubMed] [Google Scholar]

4. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab. 2002;87:489–99. [PubMed] [Google Scholar]

5. Vejbjerg P, Knudsen N, Perrild H, et al. Lower prevalence of mild hyperthyroidism related to a higher iodine intake in the population: prospective study of a mandatory iodization programme. Clin Endocrinol (Oxf) 2009;71:440–45. [PubMed] [Google Scholar]

6. Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf) 2013;78:768–76. [PubMed] [Google Scholar]

7. Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165:899–905. [PubMed] [Google Scholar]

8. Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest. 2015;38:283–94. [PubMed] [Google Scholar]

9. Winsa B, Adami HO, Bergström R, et al. Stressful life events and Graves’ disease. Lancet. 1991;338:1475–79. [PubMed] [Google Scholar]

10. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf) 2013;79:145–51. [PubMed] [Google Scholar]

11. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves’ disease. Autoimmun Rev. 2014;13:398–402. [PubMed] [Google Scholar]

12. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252–65. [PubMed] [Google Scholar]

13. Brix TH, Hegedüs L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) 2012;76:457–64. [PubMed] [Google Scholar]

14. Laurberg P, Cerqueira C, Ovesen L, et al. Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol Metab. 2010;24:13–27. [PubMed] [Google Scholar]

15. Krohn K, Paschke R. Clinical review 133: progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab. 2001;86:3336–45. [PubMed] [Google Scholar]

16. Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med. 1997;337:1675–81. [PubMed] [Google Scholar]

17. Beck-Peccoz P, Persani L. Thyrotropin-induced thyrotoxicosis. In: Braverman LE, Cooper DS, editors. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 10th Lippincott Williams & Wilkins; Philadelphia: 2013. pp. 393–99. [Google Scholar]

18. Hershman JM. Trophoblastic tumors. In: Braverman LE, Cooper DS, editors. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 10th Lippincott Williams & Wilkins; Philadelphia: 2013. pp. 409–14. [Google Scholar]

19. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88:2100–05. [PubMed] [Google Scholar]

20. Schwartz F, Bergmann N, Zerahn B, Faber J. Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. Scand J Clin Lab Invest. 2013;73:240–44. [PubMed] [Google Scholar]

21. Goichot B, Caron P, Landron F, Bouée S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf) 2015 published online May 9. DOI:10.1111/cen.12816. [PubMed] [Google Scholar]

22. Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. 2014;32:277–92. [PubMed] [Google Scholar]

23. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010;95:2715–26. [PubMed] [Google Scholar]

24. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37:691–700. [PubMed] [Google Scholar]

25. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–46. [PubMed] [Google Scholar]

26. Bahn R. The EUGOGO consensus statement on the management of Graves’ orbitopathy: equally applicable to North American clinicians and patients. Thyroid. 2008;18:281–82. [PubMed] [Google Scholar]

27. Wiersinga WM, Perros P, Kahaly GJ, et al.European Group on Graves’ Orbitopathy (EUGOGO) Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387–89. [PubMed] [Google Scholar]

28. Fatourechi V. Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab. 2012;26:553–65. [PubMed] [Google Scholar]

29. Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab. 2002;87:438–46. [PubMed] [Google Scholar]

30. Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab. 2002;87:5435–41. [PubMed] [Google Scholar]

31. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52. [PubMed] [Google Scholar]

32. Chen Q, Yan Y, Zhang L, Cheng K, Liu Y, Zhu W. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology. 2014;127:176–82. [PubMed] [Google Scholar]

33. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–43. [PubMed] [Google Scholar]

34. Traube E, Coplan NL. Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature. Tex Heart Inst J. 2011;38:225–28. [PMC free article] [PubMed] [Google Scholar]

35. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93:483–87. [PMC free article] [PubMed] [Google Scholar]

36. Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014;99:2372–82. [PubMed] [Google Scholar]

37. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. J Thyroid Res. 2014;2014:649502. [PMC free article] [PubMed] [Google Scholar] Retracted

38. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140:88–98. [PMC free article] [PubMed] [Google Scholar]

39. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115:151–62. [PubMed] [Google Scholar]

40. Meikle AW. The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid. 2004;14(suppl 1):S17–25. [PubMed] [Google Scholar]

41. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31:702–55. [PubMed] [Google Scholar]

42. de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149:526–32. [PubMed] [Google Scholar]

43. Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ. 2014;349:g5128. [PubMed] [Google Scholar]

44. Bahn Chair RS, Burch HB, Cooper DS, et al.American Thyroid Association and American Association of Clinical Endocrinologists Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646. [PubMed] [Google Scholar]

45. Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid. 2011;21:585–91. [PubMed] [Google Scholar]

46. Burch HB, Burman KD, Cooper DSA. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58. [PubMed] [Google Scholar]

47. Yamashita S, Amino N, Shong YK. The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea. Thyroid. 2011;21:577–80. [PubMed] [Google Scholar]

48. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul) 2013;28:275–79. [PMC free article] [PubMed] [Google Scholar]

49. Maia AL, Scheffel RS, Meyer EL, et al.Brazilian Society of Endocrinology and Metabolism The Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013;57:205–32. [PubMed] [Google Scholar]

50. Cappelli C, Pirola I, De Martino E, et al. The role of imaging in Graves’ disease: a cost-effectiveness analysis. Eur J Radiol. 2008;65:99–103. [PubMed] [Google Scholar]

51. Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves’ disease. Clin Endocrinol (Oxf) 2007;67:41–45. [PubMed] [Google Scholar]

52. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012;12:107–13. [PubMed] [Google Scholar]

53. Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247–55. [PMC free article] [PubMed] [Google Scholar]

54. van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Invest. 1992;15:797–800. [PubMed] [Google Scholar]

55. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724–34. [PubMed] [Google Scholar]

56. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–17. [PubMed] [Google Scholar]

57. Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid. 2005;15:835–40. [PubMed] [Google Scholar]

58. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves’ disease and modulation by methimazole therapy. Thyroid. 2013;23:1461–69. [PubMed] [Google Scholar]

59. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92:2157–62. [PubMed] [Google Scholar]

60. Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1987;65:719–23. [PubMed] [Google Scholar]

61. Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol. 2001;96:165–69. [PubMed] [Google Scholar]

62. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009;2009:132041. [PMC free article] [PubMed] [Google Scholar]

63. Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19:673–74. [PubMed] [Google Scholar]

64. Takata K, Amino N, Kubota S, et al. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves’ disease. Clin Endocrinol (Oxf) 2010;72:845–50. [PubMed] [Google Scholar]

65. Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves’ disease patients with moderate to severe hyperthyroidism. Thyroid. 2015;25:43–50. [PubMed] [Google Scholar]

66. Benker G, Reinwein D, Kahaly G, et al.European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. Clin Endocrinol (Oxf) 1998;49:451–57. [PubMed] [Google Scholar]

67. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420. [PMC free article] [PubMed] [Google Scholar]

68. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves’ disease. Eur J Endocrinol. 2006;154:783–86. [PubMed] [Google Scholar]

69. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990;70:675–79. [PubMed] [Google Scholar]

70. Anagnostis P, Adamidou F, Polyzos SA, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine. 2013;44:448–53. [PubMed] [Google Scholar]

71. Mohlin E, Filipsson Nyström H, Eliasson M. Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. Eur J Endocrinol. 2014;170:419–27. [PubMed] [Google Scholar]

72. Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves’ hyperthyroidism. Curr Opin Endocrinol Diabetes Obes. 2014;21:415–21. [PubMed] [Google Scholar]

73. Azizi F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 2006;5:107–16. [PubMed] [Google Scholar]

74. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid. 2005;15:1047–54. [PubMed] [Google Scholar]

75. Schott M, Morgenthaler NG, Fritzen R, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves’ disease. Horm Metab Res. 2004;36:92–96. [PubMed] [Google Scholar]

76. Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid. 2006;16:295–302. [PubMed] [Google Scholar]

77. Liu X, Qiang W, Liu X, et al. A second course of antithyroid drug therapy for recurrent Graves’ disease: an experience in endocrine practice. Eur J Endocrinol. 2015;172:321–26. [PMC free article] [PubMed] [Google Scholar]

78. Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf) 2012;77:310–15. [PubMed] [Google Scholar]

79. Robinson J, Richardson M, Hickey J, et al. Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J. 2014;3:245–51. [PMC free article] [PubMed] [Google Scholar]

80. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98:4776–83. [PubMed] [Google Scholar]

81. Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab. 2012;97:E49–53. [PubMed] [Google Scholar]

82. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619–29. [PMC free article] [PubMed] [Google Scholar]

83. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95:3260–67. [PubMed] [Google Scholar]

84. Noh JY, Yasuda S, Sato S, et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab. 2009;94:2806–11. [PubMed] [Google Scholar]

85. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78. [PubMed] [Google Scholar]

86. Chen DY, Schneider PF, Zhang XS, Luo XY, He ZM, Chen TH. Changes in Graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes. 2014;122:1–6. [PubMed] [Google Scholar]

87. Watanabe N, Noh JY, Kozaki A, et al. Radioiodine-associated exacerbation of Graves’ orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab. 2015;100:2700–08. [PubMed] [Google Scholar]

88. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008;69:943–50. [PubMed] [Google Scholar]

89. Träisk F, Tallstedt L, Abraham-Nordling M, et al.Thyroid Study Group of TT 96 Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700–07. [PubMed] [Google Scholar]

90. Tallstedt L, Lundell G, Tørring O, et al.The Thyroid Study Group Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med. 1992;326:1733–38. [PubMed] [Google Scholar]

91. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70. [PubMed] [Google Scholar]

92. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves’ ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23:620–25. [PubMed] [Google Scholar]

93. Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014;24:1515–23. [PubMed] [Google Scholar]

94. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86:3488–93. [PubMed] [Google Scholar]

95. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves’ disease. J Clin Endocrinol Metab. 2001;86:3016–21. [PubMed] [Google Scholar]

96. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514. [PMC free article] [PubMed] [Google Scholar]

97. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30. [PubMed] [Google Scholar]

98. Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730–37. [PubMed] [Google Scholar]

99. de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161:771–77. [PubMed] [Google Scholar]

100. Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi SR. Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. Int J Endocrinol Metab. 2014;12:e14424. [PMC free article] [PubMed] [Google Scholar]

101. Boelaert K, Syed AA, Manji N, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf) 2009;70:129–38. [PubMed] [Google Scholar]

102. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87:1073–77. [PubMed] [Google Scholar]

103. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–50. [PubMed] [Google Scholar]

104. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80. [PubMed] [Google Scholar]

105. la Cour JL, Jensen LT, Vej-Hansen A, Nygaard B. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol. 2015;172:771–78. [PubMed] [Google Scholar]

106. Ryödi E, Metso S, Jaatinen P, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab. 2015;100:3710–17. [PubMed] [Google Scholar]

107. Ceccarelli C, Canale D, Battisti P, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 2006;65:446–52. [PubMed] [Google Scholar]

108. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20:660–67. [PubMed] [Google Scholar]

109. Bojic T, Paunovic I, Diklic A, et al. Total thyroidectomy as a method of choice in the treatment of Graves’ disease—analysis of 1432 patients. BMC Surg. 2015;15:39. [PMC free article] [PubMed] [Google Scholar]

110. Palit TK, Miller CC, 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res. 2000;90:161–65. [PubMed] [Google Scholar]

111. Shinall MC, Jr, Broome JT, Baker A, Solorzano CC. Is potassium iodide solution necessary before total thyroidectomy for Graves disease? Ann Surg Oncol. 2013;20:2964–67. [PubMed] [Google Scholar]

112. Erbil Y, Ozluk Y, Giriş M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92:2182–89. [PubMed] [Google Scholar]

113. Werga-Kjellman P, Zedenius J, Tallstedt L, Träisk F, Lundell G, Wallin G. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid. 2001;11:187–92. [PubMed] [Google Scholar]

114. Pradeep PV, Agarwal A, Baxi M, Agarwal G, Gupta SK, Mishra SK. Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. World J Surg. 2007;31:306–12. discussion 313. [PubMed] [Google Scholar]

115. Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013;154:1346–52. discussion 1352–53. [PubMed] [Google Scholar]

116. Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844–52. [PubMed] [Google Scholar]

117. Akamizu T, Satoh T, Isozaki O, et al.Japan Thyroid Association Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012;22:661–79. [PMC free article] [PubMed] [Google Scholar]

118. Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am. 2012;96:385–403. [PubMed] [Google Scholar]

119. Swee DS, Chng CL, Lim A. Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. Endocr Pract. 2015;21:182–89. [PubMed] [Google Scholar]

120. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015;100:451–59. [PubMed] [Google Scholar]

121. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–77. [PubMed] [Google Scholar]

122. Pearce EN, Hennessey JV, McDermott MT. New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. Thyroid. 2011;21:573–76. [PubMed] [Google Scholar]

123. Kaykhaei MA, Shams M, Sadegholvad A, Dabbaghmanesh MH, Omrani GR. Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine. 2008;34:52–55. [PubMed] [Google Scholar]

124. Tsatsoulis A, Johnson EO, Kalogera CH, Seferiadis K, Tsolas O. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol. 2000;142:231–35. [PubMed] [Google Scholar]

125. Milner MR, Gelman KM, Phillips RA, Fuster V, Davies TF, Goldman ME. Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic symptoms. Pharmacotherapy. 1990;10:100–06. [PubMed] [Google Scholar]

126. Isozaki O, Satoh T, Wakino S, et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: The taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol (Oxf) 2015 published online Sep 21. DOI:10.1111/cen.12949. [PubMed] [Google Scholar]

127. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid. 2013;23:758–65. [PMC free article] [PubMed] [Google Scholar]

128. Andersen SL, Olsen J, Carlé A, Laurberg P. Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. J Clin Endocrinol Metab. 2015;100:1164–71. [PubMed] [Google Scholar]

129. Stagnaro-Green A, Abalovich M, Alexander E, et al.American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081–125. [PMC free article] [PubMed] [Google Scholar]

130. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2543–65. [PubMed] [Google Scholar]

131. Gianetti E, Russo L, Orlandi F, et al. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest. 2015;38:977–85. [PubMed] [Google Scholar]

132. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373–81. [PubMed] [Google Scholar]

133. Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–403. [PubMed] [Google Scholar]

134. Bowman P, Vaidya B. Suspected spontaneous reports of birth defects in the UK associated with the use of carbimazole and propylthiouracil in pregnancy. J Thyroid Res. 2011;2011:235130. [PMC free article] [PubMed] [Google Scholar]

135. Pearce EN. Thyroid disorders during pregnancy and postpartum. Best Pract Res Clin Obstet Gynaecol. 2015;29:700–06. [PubMed] [Google Scholar]

136. Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol. 2009;200:e1–6. [PubMed] [Google Scholar]

137. Ide A, Amino N, Kang S, et al. Differentiation of postpartum Graves’ thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid. 2014;24:1027–31. [PubMed] [Google Scholar]

138. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646–55. [PubMed] [Google Scholar]

139. Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid. 2013;23:269–72. [PubMed] [Google Scholar]

140. Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab. 2012;97:334–42. [PubMed] [Google Scholar]

141. Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:499–506. [PubMed] [Google Scholar]

What are the signs and symptoms with hyperthyroidism?

What are 3 symptoms of hyperthyroidism?

What are 3 causes of hyperthyroidism?

What are the 3 types of hyperthyroidism?